沙利度胺在多发性骨髓瘤中的应用：现状与未来展望 - Suppr

Suppr

超能文献

Thalidomide in multiple myeloma: current status and future prospects.

作者信息

Cavenagh Jamie D, Oakervee Heather

机构信息

St Bartholomew's and The Royal London School of Medicine and Dentistry, London, UK.

出版信息

Br J Haematol. 2003 Jan;120(1):18-26. doi: 10.1046/j.1365-2141.2003.03902.x.

DOI:10.1046/j.1365-2141.2003.03902.x

PMID:12492572

Abstract

摘要

相似文献

Thalidomide in multiple myeloma: current status and future prospects.

Br J Haematol. 2003 Jan;120(1):18-26. doi: 10.1046/j.1365-2141.2003.03902.x.

Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma.

Semin Hematol. 2003 Oct;40(4 Suppl 4):3-7. doi: 10.1053/j.seminhematol.2003.09.006.

Trials investigate first-line thalidomide in multiple myeloma.

Lancet Oncol. 2005 Jan;6(1):6. doi: 10.1016/s1470-2045(04)01696-1.

Thalidomide in newly diagnosed multiple myeloma and overview of experience in smoldering/indolent disease.

Semin Hematol. 2003 Oct;40(4 Suppl 4):17-22. doi: 10.1053/j.seminhematol.2003.09.007.

Thalidomide in relapsed/refractory multiple myeloma: pivotal trials conducted outside the United States.

Semin Hematol. 2003 Oct;40(4 Suppl 4):8-16. doi: 10.1053/j.seminhematol.2003.09.008.

The future role of thalidomide in multiple myeloma.

Acta Haematol. 2005;114 Suppl 1:18-22. doi: 10.1159/000087040.

Thalidomide in multiple myeloma.

Oncology (Williston Park). 2000 Dec;14(12 Suppl 13):11-6.

Thalidomide gives food for thought in multiple myeloma.

Lancet Oncol. 2006 Apr;7(4):283-4. doi: 10.1016/s1470-2045(06)70631-3.

Efficacy and safety of thalidomide in the treatment of multiple myeloma.

Acta Pol Pharm. 2008 Nov-Dec;65(6):771-4.

Thromboembolic events during treatment with thalidomide.

Blood. 2002 Jun 1;99(11):4247-8. doi: 10.1182/blood-2001-12-0245.

引用本文的文献

Thalidomide-induced sinus bradycardia in Crohn's disease: case report and literature review.

J Int Med Res. 2019 May;47(5):2228-2233. doi: 10.1177/0300060519833293. Epub 2019 Mar 5.

Acute Pulmonary Toxicity from Thalidomide in a Patient with Multiple Myeloma.

Radiol Case Rep. 2015 Dec 7;2(2):41-3. doi: 10.2484/rcr.v2i2.71. eCollection 2007.

Treatment with Thalidomide and Cyclophosphamide (TCID) is Superior to Vincristine (VID) and to Vinorelbine (VRID) Regimens in Patients with Refractory or Recurrent Multiple Myeloma.

Indian J Hematol Blood Transfus. 2012 Jun;28(2):67-76. doi: 10.1007/s12288-011-0103-1. Epub 2011 Aug 18.

Bortezomib: the evidence of its clinical impact in multiple myeloma.

Core Evid. 2006;1(4):265-77. Epub 2006 Jun 30.

Initial cytoreductive treatment with thalidomide plus bolus vincristine/doxorubicin and reduced dexamethasone followed by autologous stem cell transplantation for multiple myeloma.

Invest New Drugs. 2011 Feb;29(1):175-81. doi: 10.1007/s10637-009-9343-4. Epub 2009 Oct 13.

Evolving treatment strategies for myeloma.

Br J Cancer. 2005 Jan 31;92(2):217-21. doi: 10.1038/sj.bjc.6602341.

An evaluation of factors predicting long-term response to thalidomide in 234 patients with relapsed or resistant multiple myeloma.

Br J Cancer. 2004 Nov 29;91(11):1873-9. doi: 10.1038/sj.bjc.6602225.

Management of thalidomide toxicity.

J Support Oncol. 2003 Sep-Oct;1(3):194-205.

Thalidomide-induced severe neutropenia during treatment of multiple myeloma.

Int J Hematol. 2004 Apr;79(3):283-8. doi: 10.1532/ijh97.03136.

Innovative strategies in lymphoma therapy.

Wien Klin Wochenschr. 2003 Aug 14;115(13-14):462-70. doi: 10.1007/BF03041029.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验